Metabolic pathways of flobufen - A new antirheumatic and antiarthritic drug. Interspecies comparison

Experimental and Toxicologic Pathology

Volumn 51, Issue 4-5, 1999, Pages 352-356

  Kvasnicková, Eva ^a   Szotáková, Barbora ^a   Wsól, Vladimír ^a   Trejtnar, František ^a   Skálová, Lenka ^a   Hais, Ivo M ^a   Kuchar, Miroslav ^b   Poppová, Marie ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b Research Institute of Pharmacy and Biochemistry Prague   (Czech Republic)

Author keywords

Antiarthritic drugs; Antiphlogistic drugs; Antirheumatic drugs; Cytochrome P 450; Drug biotransformation; Flobufen; Microsomal reduction

Indexed keywords

ACETIC ACID; ARYLACETIC ACID DERIVATIVE; CYTOCHROME P450; FLOBUFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; BIOLOGICAL MODEL; CELL FRACTIONATION; CONFERENCE PAPER; DRUG TRANSFORMATION; ENZYME ACTIVITY; GUINEA PIG; LIPOPHILICITY; LIVER CELL; LIVER MICROSOME; MALE; MUSCLE TISSUE; NONHUMAN; RABBIT; RAT; RHEUMATOID ARTHRITIS;

ANIMALIA; CAVIA PORCELLUS; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0344258325     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(99)80020-7     Document Type: Conference Paper

References (16)

1. BERRY MM, FRIEND DS: High yield preparation of isolated rat liver parenchymal cells, a biochemical and fine structural study. J Cell Biol 1969; 43: 506-520.
2. FLOWER RJ, VANE JR: Inhibition of prostaglandin biosynthesis. Biochem Pharmacol 1974; 23: 1439-1450.
3. GATT S, BREMER J, OSMUNDSEN H: Pyrene dodecanoic acid coenzyme A ester: peroxisomal oxidation and chain shortening. Biochim Biophys Acta 1988; 958: 130-133.
4. GOEPTAR AR, SCHEERENS H, VERMEULEN NPE: Oxygen and xenobiotic reductase activities of cytochrome P-450. CRC 1995; 25: 25-65.
5. GORES GJ, KOST LJ, LAROSSO NL: The isolated perfused rat liver: conceptual and practical cosiderations. Hepatology 1986; 6: 511-517.
6. HADDOCK RE, JEFFERY DJ, MANGAN FR, PARDONI IS: Penetration of nabumetone into inflammatory exudates in the rats. J Pharm Pharmacol 1983; 35: 358-362.
7. KORUNA I, MATEJÍČKOVÁ M, PATEROVÁ M, et al.: In vivo metabolites of flobufen in Man. Research Report, Research Institute for Pharmacy and Biochemistry, Prague 1991.
8. KUCHAR M, MATUROVÁ E, BRUNOVÁ B, et al.: Quantitative realtions between structure and antiinflammatory activity of aryloxoalkanoic acids. Collec Czechoslovak Chem Commun 1988; 53: 1862-1872.
9. KUCHAR M, VOSÁTKA V, POPPOVÁ M, et al.: Some analogs of 4-(2′,4′-diflourobiphenyl-4-yl)-4-oxobutanoic acid: synthesis and antiinflammatory activity. Collect Czech Chem Commun 1995; 60: 1026-1033.
10. LAZAROV PB: Rat liver peroxisomes catalyse the (oxidation of fatty acids. J Biol Chem 1978; 253: 1522-1528.
11. MEADE EA, SMITH WL, DEWITT DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1992; 266: 6610-6614.
12. OSMUNDSEN H, BREMER J, PEDERSEN JI: Metabolic aspects of peroxisomal β-oxidation. Biochim Biophys Acta 1991; 1085: 141-158.
13. PANAJOTOVÁ V, ANDEROVÁ E, JANDERA A, KUCHAR M: Pharmacological profile of the novel potent antirheumatic 4-(2′, 4′-difluorobiphenyl-4-yl)-2-methyl-.4-oxobutanoic acid. Arzneimittelforschung 1997; 47: 648-652.
14. VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232-235.
15. VANE JR, BOTTING RM: New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10.
16. YAMADA J, HORIE S, WATANABE T, SUGA T: Participation of peroxisomal β-oxidation systém in the chain-shortening of xenobiotic acyl compound. Biochem Biophys Res Commun 1984; 125: 123-128.